Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone858-320-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.25 million
Profitability
Miscellaneous
Employees95
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) posted its earnings results on Monday, August, 12th. The medical research company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.19. The medical research company earned $1.19 million during the quarter. Biocept had a negative net margin of 672.27% and a negative return on equity of 263.98%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 Wall Street analysts have issued 1-year target prices for Biocept's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Biocept's stock price to reach $3.00 in the next year. This suggests a possible upside of 248.9% from the stock's current price. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
What are Wall Street analysts saying about Biocept stock?
Here are some recent quotes from research analysts about Biocept stock:
- 1. Maxim Group analysts commented, "Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet." (5/9/2019)
- 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019)
Has Biocept been receiving favorable news coverage?
Media coverage about BIOC stock has trended somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biocept earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Biocept.
Are investors shorting Biocept?
Biocept saw a increase in short interest in August. As of August 31st, there was short interest totalling 723,000 shares, an increase of 8.3% from the July 31st total of 667,700 shares. Based on an average daily trading volume, of 1,450,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.2% of the shares of the company are sold short. View Biocept's Current Options Chain.
Who are some of Biocept's key competitors?
What other stocks do shareholders of Biocept own?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg, Director of Technology Devel.
Who are Biocept's major shareholders?
Which institutional investors are buying Biocept stock?
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $0.8599.
How big of a company is Biocept?
What is Biocept's official website?
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
